Loading search results
Natural History Study of KSHV-Associated Multicentric Castleman's Disease
Sponsor study identifier
Secondary identifiers
observational
195
1 country
1
Study Start
November 17, 2021
Actual (reported)Primary Completion
January 1, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 1, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Background: Kaposi s sarcoma herpes virus (KSHV) causes several kinds of cancer, Kaposi sarcoma (KS), a form of Multicentric Castleman s Disease (MCD) and a type of lymphoma known as Primary Effusion Lymphoma (PEL). These cancers can occur alone or at the same time in the same patient. MCD can cause a lot of symptoms and problems with various organs in the body, making patients feel quite unwell. If unrecognized, the disease can be fatal. Medications such as rituximab alone or in combination with chemotherapy may help treat MCD but there is little known about the long term effects and the natural course of MCD. Objective: To better understand the biology of KSHV-MCD to help identify how this disease causes illness and how cancer treatments known to be effective in MCD may help patients with this condition. This study also aims to help identify ways to treat the disease by providing other standard cancer treatments that would be useful to use to treat MCD based on what we know about this condition. Eligibility: People 18 years of age and older with KSHV-MCD. Design: Participants will be screened with: Medical history Physical exam CT scan Blood and heart tests Participants will have an initial evaluation. This will include: Review of participants symptoms and ability to perform their normal activities Blood and urine tests Imaging studies such as CT and PET scans. Participants may have a contrast agent injected into their arm. Photographs to document skin lesions Optional skin biopsy. For this, a small piece of the skin will be removed. Optional lymph node needle biopsy Optional samples of the fluid in the space around the lungs, intestines, or heart Optional sample of the liquid that surrounds the brain and spinal cord Saliva samples DEXA scan to examine the bones Questionnaires Optional limb measurements or cognitive tests Physicians will give participants recommendations about treatment. After their initial evaluation and any treatment, participants will have additional visits. These will occur every 3 months for the first year, then every 6 months for the second year, and then once a year for up to 1 year.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 1, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 17, 2021
Actual (reported)July 20, 2021
Actual (reported)November 17, 2021
Actual (reported)January 1, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
January 1, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
natural history of MCD
clinical presentation, patterns of disease progression, therapeutic response, disease recurrence and participant overall survival
ongoing
concurrent KS or PEL evaluation
every 3 months for year 1, every 6 month for year 2, yearly from year 3
relapse-free survival
every 3 months for year 1, every 6 month for year 2, yearly from year 3
overall survival
every 3 months for year 1, every 6 month for year 2, yearly from year 3
Subjects with KSHV-associated MCD
primary clinical
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Ramya M Ramaswami, M.D.
National Cancer Institute (NCI)
First Submitted
July 17, 2021
First Posted
July 20, 2021
Study Start
November 17, 2021
Actual (reported)Primary Completion
January 1, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Contact the study team to confirm eligibility.
Study Completion
January 1, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 16, 2026
Record last verified: 2026-10-13
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: